[Featured Stock] BioSmart Rises on News of Diagnostic Kit Development
On the 2nd, the KOSPI and KOSDAQ indices started lower influenced by the decline in the US stock market. Dealers are working in the Hana Bank dealing room in Euljiro, Seoul. Photo by Moon Honam munonam@
View original image[Asia Economy Reporter Junho Hwang] AMS Bio's PCR diagnostic kit, which can detect all COVID-19 variants including Omicron, has led to a strong rise in the stock price of its largest shareholder, BioSmart, on the 2nd.
As of 10:08 AM on the same day, BioSmart's stock was trading at 6,190 KRW, up 22.09% compared to the previous trading day.
AMS Bio announced that its PCR diagnostic kit can detect all COVID-19 variants including Omicron. This product is currently being sold domestically and exported.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Current State of K-Finance for Foreign Nationals]①From Niche to Core... Banks Go All-In on First-Mover Competition
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Meanwhile, BioSmart is a company that began manufacturing and supplying the first MS CARD in Korea in 1983. It holds a 76% stake in AMS Bio.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
